| 查看: 201 | 回复: 0 | |||
| 当前主题已经存档。 | |||
abcd888898银虫 (正式写手)
|
[交流]
【转帖】Novo Nordisk starts phase 1 trial with long-acting oral GLP-1 analogue
|
||
|
Emisphere earns 2 million US dollar milestone payment(13 Jan 2010) Novo Nordisk today announced that it has initiated its first phase 1 clinical trial with a long-acting oral GLP-1 analogue (NN9924). This milestone releases a 2 million dollar payment to Emisphere Technologies, Inc., whose proprietary Eligen® Technology is used in the formulation of NN9924. GLP-1 (Glucagon-Like Peptide-1) is a natural hormone involved in controlling blood sugar levels. It stimulates the release of insulin only when blood sugar levels become too high. In people with type 2 diabetes, GLP-1 secretion is often impaired. The aim of the trial, which is conducted in the UK, is to investigate the safety, tolerability and bioavailability of NN9924 in healthy volunteers. Results from the trial, which is planned to enrol about 155 people, are expected to be reported in 2011. There are many challenges in developing a formulation of GLP-1 for oral use, in particular obtaining adequate bioavailability (absorption of the drug in the body). NN9924 addresses some of the key challenges, and utilises the Eligen® formulation technology from Emisphere to facilitate GLP-1 absorption from the gut. |
回复此楼» 猜你喜欢
药学专硕申博
已经有18人回复
-
070700求调剂
已经有1人回复
-
药理学论文润色/翻译怎么收费?
已经有122人回复
-
求调剂总分327
已经有1人回复
-
可能上不了岸？有条件的可以考虑其他出路
已经有0人回复
-
BL21(DE3)UV或者丝裂霉素诱导条件下会释放DE3的噬菌体吗？
已经有479人回复
-
分子对接相关经验分享
已经有0人回复
-
分子对接相关经验分享
已经有0人回复
-
2026生物医药产业发展大会
已经有0人回复
20